IVI in the Media

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

Vaccine Training Course For Developing Countries

Author
Margaret
Date
2014-05-12 00:00
Views
4821

 

Professor Wan-Kyoo Cho of the Korea Support Committee for IVI delivers the Welcome Address at the 14th International Vaccinology Course for the Asia Pacific Region at the Institute’s headquarters in Seoul on Monday. The weeklong course, which is designed to boost developing country capacities in vaccine research and immunization, has more than 70 participants from over 20 countries worldwide.

 

IVI Hosts 14th Advanced Vaccinology Course to Increase Developing Countries’ Capacity in Vaccine Research and Immunization

 

l 71 trainees from 20 countries participate in this year’s course, which runs from May 12-16 at IVI headquarters

l Course helps better equip healthcare professionals and policy-makers in developing nations with latest knowledge in vaccine science, vaccination, and shared practical experience

l More than 30 experts from international agencies, research institutions, industry and non-profit organizations, including IVI, the World Health Organization and the U.S. National Institutes of Health will serve as faculty members

 

May 12, 2014, Seoul, South Korea— The International Vaccine Institute (IVI), the first international organization hosted by the Republic of Korea, convenes the 14th Advanced Vaccinology Course in the Asia-Pacific Region from May 12 to 16. The annual course aims to build capacity of health professionals and decision-makers, especially those from developing countries, in the entire vaccine continuum spanning vaccine development, evaluation, production and policy.

 

This year, the highly subscribed course brings together 71 trainees from 20 countries worldwide including Sudan, Yemen, Ethiopia, Ghana, Nepal, China, and Spain. The trainees are a diverse mix of scientists, public health officials, and policymakers from the private and public sectors. They include 15 developing country participants who are invited through fellowships funded by course sponsors.

 

“This year’s course focuses on the vaccine discovery, development and delivery process,” said Deborah Hong, Head of IVI’s Communications and Advocacy Unit and member of the Organizing Committee. “The course will also entail discussions about vaccine-preventable diseases including cholera, dengue, and enteric fever, and other topics such as public perceptions about vaccines and ethics in clinical trials.” 

 

Lectures by leading experts in vaccinology and interactive case studies will comprehensively cover disciplines and issues including epidemiology and immunology, vaccine discovery to licensure, licensing to introduction, licensure to use, and use to acceptance. More than 30 experts from international agencies, including IVI and the World Health Organization; research institutions, including the U.S. National Institutes of Health; universities, including London School of Hygiene and Tropical Medicine; industry, and non-profit organizations will serve as faculty members.

 

Professor Baik Lin Seong from Yonsei University in Seoul will deliver a plenary speech entitled “Future Outlook: The Role of Korea on Vaccines for Global Health” on May 16. Additionally, Dr. Youngmee Jee from the WHO Regional Office for the Western Pacific will give a lecture entitled “Global and Regional Vaccine Action Plan:  40 Years of Expanded Program on Immunization” to give a historical overview of the EPI program. Other topics to be covered during the course include ‘Use of New Vaccines in School Settings – an Example of Typhoid,’ and ‘Regulatory Considerations in Vaccine Clinical Trials.’  

 

“Capacity building of developing countries is an integral part of IVI’s mandate to develop safe, effective, and affordable vaccines and make them available to populations in developing nations,” said Dr. Thomas F. Wierzba, Deputy Director General of Vaccine Development & Delivery at IVI. “IVI will continue to provide quality training for healthcare professionals and vaccine scientists to ensure wider use of vaccines by populations in need, and seek to develop a network among course alumni to expedite post-event exchange and communications.”

 

The weeklong course is sponsored by GlaxoSmithKline Biologicals, Korea Exchange Bank Foundation, and Pfizer.  Core support is provided by the Swedish International Development Cooperation Agency (Sida), and the Korean Ministry of Education.

 

About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 36 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.

 

 

 

 

Media Contact:

 

IVI

Tae Kyung Byun

Public Awareness/Advocacy Officer, IVI

Phone: +82-2-872-2801 (Ext. 159)     

Mobile: +82-10-8773-6071

Email: tkbyun@ivi.int

 

Burson-Marsteller Korea

Lirah Lim

Phone: +82-3782-6469

Mobile: +82-10-2081-0643

Email: lirah.lim@bm.com

 

Nicolle Kuritsky

Mobile: +82-10-3889-8902

Email: nicolle.kuritsky@bm.com  

 

 

 

 

DONATE